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Changes in erythropoiesis in hereditary
hemochromatosis are not mediated by HFE
expression in nucleated red cells
Hereditary hemochromatosis is anautosomal recessive disorder char-acterized by increased iron absorp-
tion and storage of iron in parenchymal tis-
sues.1 In 1996, Feder et al.2 cloned the HFE
gene and found that 85% of US hemochro-
matosis patients were homozygous for the
mutation C282Y, whilst many of the
remainder were compound heterozygotes
for C282Y and a common second variant,
H63D. In the UK over 90% of patients are
homozygous for C282Y.3 The mutant HFE
alleles are common in the UK, with allelic
frequencies of about 8% for C282Y and
15% for H63D.4 Thus around 1 in 150 of
the general UK population are homozy-
gous for HFE C282Y.
The HFE protein encodes an MHC class I
molecule that forms a functional het-
erodimer with β2-microglobulin.5 C282Y,
but not the H63D variant, disrupts both the
association with β2-microglobulin and the
subcellular distribution of HFE.5 Normal
HFE has been co-immunoprecipitated with
the transferrin receptor from placenta6 and
from human duodenum,7 suggesting that
the function of HFE is to alter the kinetics
of transferrin receptor mediated iron
uptake. Further evidence that HFE alters
transferrin iron uptake comes from studies
in which HFE has been over-expressed in
cell lines. Feder et al.8 found that HFE low-
ered the affinity of transferrin receptor for
diferric transferrin, whilst several studies
have demonstrated reduced iron uptake
from transferrin by cells over-expressing
HFE.9-12 One of the key problems in under-
standing how HFE mutations may lead to
the development of iron overload is to
determine how HFE protein expression
alters iron turnover in the body. The HFE
protein is strongly expressed in placenta,6
the duodenal crypts7 and in Küpffer cells of
the liver.13 Thus major sites of HFE expres-
sion coincide with principal sites of iron
handling. It might be supposed that if HFE
expression prevents the uptake of excess
iron then in genetic hemochromatosis, in
which HFE function is compromised,
patients would accumulate iron at these
sites. However, villus epithelial cells and
the Küpffer cells of the liver contain little
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Background and Objectives. The HFE protein interacts with the transferrin receptor
(TfR) to regulate cellular iron uptake. Nucleated erythroid cells have the highest num-
ber of TfR and the greatest iron uptake.  The aim of this study was to investigate
whether erythroid iron uptake is directly affected by HFE mutations.
Design and Methods. Iron status and erythropoiesis was investigated in sixty, asymp-
tomatic HFE C282Y homozygotes. Reverse transcription-polymerase chain reaction,
flow cytometry and immunocytochemistry were employed to investigate the HFE
expression profile of normal peripheral blood, nucleated erythroid cells and several cul-
tured cell lines.
Results. The HFE C282Y homozygous subjects showed subtle erythropoietic changes
with raised transferrin saturation and reticulocyte counts and low-normal serum trans-
ferrin receptor levels, but normal erythrocyte count and mean cell volume. HFE mRNA
was detected in macrophages and monocytes and HFE protein was detected in granu-
locytes and at low levels in monocytes. Cultured primary human erythroid colonies did
not express HFE mRNA or protein.
Interpretation and Conclusions. There is evidence that HFE C282Y homozygotes dis-
play increased plasma iron turnover and increased erythropoiesis, despite there being
no evidence that HFE is expressed in erythroid colonies with a normal HFE genotype.
It is likely that HFE mutations do not directly alter erythroid iron handling, but alter the
supply of iron to the erythroid tissues.
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iron in patients with genetic hemochromatosis.1
Similar findings have been reported for the‚ β2-micro-
globulin knock-out mouse14 and the HFE knockout
model.15 In addition, the transfection of wildtype HFE
into monocytes from hemochromatosis (C282Y
homozygous) patients resulted in increased iron and
ferritin accumulation.16 Townsend and Drakesmith17
reported a similar finding in the reticuloendothelial cell
line THP-1 and hypothesized that HFE may act, in
some cells, by inhibiting the export of iron from cells,
perhaps by interaction with ferroportin. There is evi-
dence of some disturbance of erythropoiesis in
patients with genetic hemochromatosis, including a
raised red cell hemoglobin concentration and
increased mean cell volume (MCV).18 Ferrokinetic
comparisons of hemochromatosis patients and nor-
mal subjects have revealed that there is a 40%
increase in plasma iron turnover in hemochromatosis
patients.19 Cavill et al.20 demonstrated that this was
attributable to increased erythropoietic turnover.
Furthermore, erythroid iron uptake occurs via trans-
ferrin receptor mediated endocytosis, the process
that has been shown to be altered by HFE expression
(see earlier). Until now, there have been no reports of
the pattern of HFE expression in the erythroblast
marrow, the major site of iron deployment.
Investigation of the pattern of HFE expression in ery-
throid precursors is therefore of particular impor-
tance to the understanding of the role of HFE protein
in iron handling and the effects of the HFE mutations
for hemochromatosis patients.
The implications of altered erythroid iron handling
in hemochromatosis may be far reaching as it has
been proposed that increased erythroid iron turnover
alone could drive an increased plasma iron turnover,
leading to the iron overload seen in hemochromato-
sis patients.21 In this study, we further investigated
the erythroid iron demands of subjects homozygous
for HFE C282Y and the distribution of HFE mRNA
and protein expression among cultured primary
human erythroid cells.
Design and Methods
Subjects
In a survey of 10,500 blood donors4 72 were found
to be homozygous for C282Y. Sixty-five of these
were later interviewed and a further blood sample
was taken to confirm the genetic test result, to carry
out a blood count and to determine serum ferritin,
transferrin saturation and serum transferrin receptor
concentration. Of these, 60 had neither been treated
for iron overload nor given blood within one month
of the interview. This study was approved by the
Local Research Ethics Committee. Peripheral blood
samples for HFE expression studies were obtained
from control subjects who had been tested for HFE
C282Y and H63D mutations (laboratory staff mem-
bers who gave informed consent).
Laboratory investigations
Blood counts were made using the Advia 120.
Serum ferritin concentrations were determined with
the Roche 2010 immunoanalyzer and serum iron,
unsaturated iron binding capacity and transferrin sat-
uration were determined as described by
Worwood.22 Serum transferrin receptor concentra-
tions were determined with the Orion IdeA kit
(Orion Comporitu, Espoo, Finland).
Cells
Human cell lines
Human cell lines CCF-STTG1 (astrocytoma),
CACO-2 (colon adenocarcinoma), Hep G2 (hepato-
cyte carcinoma) and V937 (histiocytic lymphoma)
were obtained from the European Collection of
Animal Cell Lines (Porton Down, Salisbury, UK) and
cultured under the recommended conditions. The
human B-lymphocyte line SUPT13 was kindly pro-
vided by Mr. S. Austin (Hematology Department,
University Hospital of Wales).
Mononuclear cells 
Mononuclear cells were purified from peripheral
blood by density gradient separation with Lympho-
prep (Life Technologies International).  Monocytes
and lymphocytes were separated according to their
scatter characteristics using a FACSIII cell sorter
(Beckton Dickinson). Granulocytes were separated
from mononuclear cells and erythrocytes on Mono-
Poly resolving medium (ICN). Purity was established
by staining cytospin preparations with hematoxylin
and eosin followed by examination under the light
microscope. In terms of nucleated cells, each prepara-
tion was >95% pure. Granulocyte preparations con-
tained some erythrocytes.
Macrophages
Macrophages were obtained by culturing normal
peripheral blood mononuclear cells in RPM1-1640
medium containing 10% fetal calf serum in 25 cm2
flasks for one week. Macrophages were harvested by
discarding the culture medium and non-adherent
cells followed by release of the macrophages by
adding 3 mL trypsin-EDTA solution, incubating for
10 minutes at 37°C and scraping. The macrophages
were washed in medium, and the samples split to
prepare both cytospin slides and RNA.
Culture of erythroid colonies
Platelet-depleted, non-adherent mononuclear cells
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from normal peripheral blood were cultured at
4x10
5
/mL in semi-solid conditions using 0.9%
methylcellulose (A4 Premium, Dow Chemicals,
Orpington, UK) in serum-free medium.23 Briefly, this
medium was based on Iscove’s modified Dulbecco’s
medium (Gibco BRL, Paisley, UK) and contained
deionized bovine serum albumin, cholesterol, bovine
insulin and α-monothioglycerol (all from Sigma,
Poole, UK) and human, 30%-iron saturated transferrin
(Boehringer Mannheim, Bracknell, UK). Recombinant
human interleukin-3 (Sandoz, Bordon, Hants, UK)
was added at 2.5 ng/mL and recombinant human
erythropoietin (Roche, Lewes, UK) at 2 U/mL. Six 0.5
mL aliquots were cultured in each of two 24-well tis-
sue culture plates (Nunc, Fisher, Loughborough, UK)
with sterile distilled water placed in the outer wells
to maintain humidity. The cells were incubated for
11 days at 37°C in a humidified incubator with 5%
CO2 in air. Burst-forming units erythroid (BFU-E)
were sufficiently hemoglobinized by 10 days to
allow easy visual identification using a Leitz Diavert
inverted microscope. Individual BFU-E were extract-
ed using a Gilson P20 micropipette. BFU-E from each
well were pooled in 200 µL sterile PBS with 0.1%
bovine serum albumin (Sigma). The study was
repeated with cells harvested at 10 and 14 days.
Preparation of RNA
Cell pellets (approx. 5×106 cells) were lysed in 0.5-1
mL Rnazol B (Biogenesis), followed by vigorous vor-
texing of the suspension and storage at –70°C. RNA
was extracted by the acid-guanidium isothiocyanate,
phenol chloroform method designed by Chomczynski
and Sacchi.24
Reverse transcription polymerase chain reac-
tion
(RT-PCR)
Reverse transcription reactions were performed
using the PE Applied Biosystems RNA, PCR Core Kit.
HFE expression was detected with primers designed
to amplify reverse transcribed HFE mRNA to produce
a cDNA PCR product of 354bp and to amplify HFE
genomic DNA to produce a PCR product of 563bp. β2
microglobulin mRNA was amplified to produce a PCR
product of 306bp. There was no amplification of a β2
microglobulin PCR product from genomic DNA using
the RT-PCR primers because of the long intronic
sequence between the primers. RT-PCR to detect HFE
expression was performed using the upstream primer
5’ cag gac ctt ggt ctt tcc ttg ttt g 3’ at 1 µM and the
downstream primer 5’ tgc tct cca atc cag tgt gtc agg 3’
at 1 µM. The cycling conditions were: 1 cycle at 95°C
for 120s then 38 cycles of 95°C for 40s, 62°C for 40s
and 72°C for 60s. The Taq polymerase was Amplitaq
(Applied Biosystems, Warrington, UK). The assay
was controlled by amplification of β2 microglobulin
from the same cDNA samples using the primers 5’ ctt
agc tgt gct cgc gct ct 3’ and 5’ gac aaa gtc aca tgg ttc
aca cgg 3’, both at 0.25 µM final concentration. The
cycling conditions for the PCR were identical to
those for the HFE amplification. The PCR products
were analyzed by agarose gel electrophoresis. 
HFE antiserum  
The rabbit antiserum to a C-terminal peptide from
HFE7 (‘CT-16 antibody’) was kindly supplied by Dr.
W. Sly, St. Louis University.
Flow cytometry using the CT-16 antibody
Peripheral blood cells (whole blood) were fixed
(Leukoperm Kit, Serotec, Oxford,UK) and washed in
phosphate-buffered saline (PBS). Two aliquots were
incubated with 5 µL anti-CD68:FITC antibody
(Dako, Ely, UK), and another two were stained with
5 µL control anti-rabbit IgG:FITC antibody (Dako).
After 15 min incubation at room temperature, two
aliquots, one with and one without the FITC-labeled
antibody marker, were incubated with CT-16 anti-
serum, whilst the other two samples were incubated
with non-immune rabbit serum (final dilutions 1:40).
Finally cells were incubated with goat anti-rabbit:PE
antibody (Sigma, 1 in 8 dilution). The samples were
washed, resuspended in 1 mL PBS, and analyzed
immediately using a FACSIII flow cytometer
(Beckton Dickinson).  
The flow cytometry data were analyzed using Win
MDI software. Monocytes were gated according to
CD68 staining. Lymphocytes and granulocytes were
gated according to their forward and side scatter
characteristics. Histograms of each gated cell popula-
tion stained with control non-immune serum and
CT16 serum were compared in order to recognize
HFE staining.
Fluorescent staining of cytospin preparations
Cytospin preparations of peripheral blood leuko-
cytes and pooled BFU-E were air dried, fixed in
methanol for 5 minutes, dried, then incubated with
0.5% BSA in 50 mM Tris buffered saline (TBS) pH 7.5
for 30 minutes. The leukocyte slides were washed
twice in TBS and stained with 1/100 dilution of CT-
16 in 0.5% BSA in TBS for 1 hour at room tempera-
ture. A control slide was incubated with a 1/100 dilu-
tion of normal rabbit serum. The slides were washed
three times in TBS, then stained with goat anti-rabbit
immunoglobulins conjugated with PE (1 in 40 dilu-
tion, P-8172 Sigma) for one hour. The slides were
washed three times in TBS, incubated with mouse
anti-actin monoclonal antibody (1/20, A4700 Sigma),
washed three times in TBS and incubated with goat
anti-mouse IgG Fab specific, FITC conjugate (1 in 40
G.P. Feeney et al.
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dilution, F4018 Sigma) to detect all of the cells pres-
ent. For BFU-E the cells were incubated with a 1 in
100 dilution of CT16 primary antibody (control cells
with 1 in 100 dilution of normal rabbit serum) fol-
lowed by a 1 in 40 dilution of goat anti-rabbit IgG
FITC conjugate (F-1262 Sigma). Cells were then
stained with a 1 in 50 dilution of RPE-conjugated
mouse anti-glycophorin A (Dako). Control cells were
stained with RPE-conjugated mouse IgG1 (Dako).
The slides were washed in TBS, in sterile water,
mounted using glycergel aqueous mountant (Sigma)
and inspected using a fluorescent microscope (Zeiss
Axiophot). Images were captured with a digital cam-
era, using equivalent exposure settings for each sam-
ple in order to allow a direct comparison of CT16
antiserum staining.
Results
Erythropoiesis in asymptomatic subjects 
homozygous for HFE C282Y
The median interval between the last blood dona-
tion and testing was 217 days. Over the previous 3
years the men had donated 3.9±1.4 (SD) units of
whole blood and the women 2.8±1.6 units.
Hematology and iron status are summarized in Table
1. None of the subjects was anemic, the red cell count
and MCH were normal but the mean reticulocyte
count was raised. This did not correlate with fre-
quency of blood donation, time elapsed since last
donation, or transferrin saturation. The percentage
reticulocyte count (mean 2.0%) was also above the
reference range (0.5-1.6%). The transferrin saturation
was > 50% in 10 of 36 women (28%) and 144 of 24
men (58%). Most subjects had normal levels of
serum ferritin (male, 15-300 µg/L and female 15-200
µg/L). One man had serum ferritin >1,000 µg/L and
three women had serum ferritin <15 µg/L. Median
levels of serum transferrin receptor were at the lower
border of the reference range. Stepwise regression
analysis of sTfR concentration against serum iron,
TIBC, transferrin saturation, ferritin, Hb, reticulocyte
count and frequency of blood donation revealed only
a correlation with transferrin saturation (Figure 1).
HFE expression in blood cells
HFE mRNA expression by RT-PCR
Lymphoid cell lines and all granulocyte and lym-
phocyte preparations examined were negative for
HFE expression (Table 2). The expression of the con-
trol gene, β2-microglobulin, was detected in all.
Expression was detected in 1 of 3 monocyte prepara-
tions, and in macrophages derived from cultured
monocytes. Erythroid colonies were grown from
normal, peripheral blood mononuclear cells and in
the first preparation mRNA was detected by RT-
PCR. However the colonies contained some
macrophages (derived from monocytes present in the
mononuclear cell preparation). When erythroid
colonies (harvested at 10, 12 and 14 days) were
grown from mononuclear cells from peripheral blood
depleted of monocytes, mRNA was not detectable
by RT-PCR whilst the control β2-microglobulin
mRNA was detected.
HFE protein expression
In order to characterize the expression profile of
HFE within peripheral blood leukocytes further, the
Erythropoiesis and HFE expression
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Table 1. Hematologic parameters and iron status in 60 subjects
homozygous for HFE C282Y identified by genetic testing of
10,500 blood donors.
Mean ± SD
Variable Reference range Female (n=36) Male (n=24)
Hb (g/dL) 11.5–15.5 F 13.7±0.9 15.3±1.0
13.0–16.5 M
RBC (×1012/L) 3.4–5.2 F 4.4±0.4 4.8±0.3
3.8– 5.6 M
MCH (pg) 27.0–34.0 31.4±1.5 31.7±1.4
Reticulocyte count (×109/L) 20–70 89±32 96±34
% reticulocytes 0.5–1.6 2.0±0.7 2.0±0.7
Transferrin saturation (%) <50% 44±22 58±20
Serum ferritin (µg/L)* 15–200F 55 (30–101) 236 (109–393)
15–300 M
Transferrin receptor (mg/L)* 1.3–3.3 1.3 (0.9–1.8) 1.1 (0.8–2.2)
* median (1st and 3rd quartiles).
Figure 1. Correlation between sTfR concentration and transferrin
saturation in the 44 subjects for whom sTfR concentrations were
available. The regression equation is y: 2.25 - 0.0163x, R2: 0.248,
p=0.001.
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expression of HFE protein was investigated using the
CT16 antiserum to HFE (Figure 2). The most efficient
strategy for distiguishing lymphocytes, monocytes
and granulocytes for HFE expression analysis is by
flow cytometry. Peripheral blood granulocytes con-
tain multi-globular nuclei and have a highly granular
cytoplasm; these gross morphological features alter
the light scatter characteristics of cells such that they
can be readily identified, using flow cytometry, in
non-malignant peripheral blood samples solely on
the basis of their increased side scatter (Figure 2A)
compared to that of lymphocytes and monocytes
(granulocytes are gated as R2 and colored green in
the dot plots). The lymphocytes and monocytes can
also be distinguished by subtle differences in their
scatter characteristics, although it is more reliable to
use an antigenic marker unique to one cell type.
Expression of CD68 (detected on the FL-2 channel)
was used in this instance to identify monocytes pos-
itively (gated R1 and colored red in dot plots, Figure
2A).  The remaining cells with low forward and side
scatter characteristics were regarded as being lym-
phocytes (gated R3 and colored blue in the dot plots).
Having identified the respective cell populations,
comparisons of HFE staining to control non-immune
Table 2. HFE mRNA expression in various tissues, cultured primary
cells and cell lines.
Cell type HFE expression
(++, +, or none)
CCF-STTG1 (human astrocytoma) ++
CACO-2 (human colon adenocarcinoma) ++
HepG2 (human hepatocyte carcinoma) ++
U937 (human histiocytic lymphoma) Negative
SUPT13 (human B-lymphocyte line) Negative
Human duodenal biopsy ++
Undifferentiated K562 cells (human CML) ++
Cultured vascular endothelial cells +
Peripheral blood monocytes 1/3 +
Peripheral blood lymphocytes Negative
Macrophages derived from PB monocytes ++
Peripheral blood reticulocytes Negative
Peripheral blood granulocytes Negative
Erythroid colonies (from monocyte-depleted Negative
mononuclear cells) harvested at day 10 and 11 
Figure 2A. Flow cytometry analysis of HFE expression in normal periph-
eral blood. Dot plots of peripheral blood flow cytometry data showing
the gating used for analysis. The top two dot plots in each column
show the scatter characteristics of the peripheral blood cells stained
with CD68 antibody and non-immune serum (CD68/Con) and of the
peripheral blood cells stained with CD68 antibody and with CT16 HFE
antibody (CD68/HFE). Below these are the dot plots of fluorescence
for the same samples: FL-1 represents FITC fluorescence (CD68 stain-
ing), whilst FL-2 represents phycoerythrin fluorescence (HFE staining).
The HFE staining of the granulocytes (green) can be seen clearly. The
bottom dot plots shows the fluorescence of cells stained with control-
FITC antibody and for HFE with CT16 antibody (Con/HFE) together with
the dual control stain (Con/Con). The logic gates R1 for monocytes, R2
for granulocytes and R3 for lymphocytes are shown.
Figure 2B. Flow cytometry analysis of HFE expression in normal
peripheral blood. The pattern of HFE expression in normal peripheral
blood is illustrated as histograms of phycoerythrin fluorescence for the
different peripheral blood cell subsets which are distinguished according
to the gating shown in Figure 2A. The red histograms represent fluores-
cence for cells stained with control non-immune rabbit serum, whilst the
overlaid unshaded histograms represent staining for HFE using the CT16
polyclonal antibody. The all cells histogram shows that a subset of
peripheral blood cells stained for HFE, whilst many did not. Monocytes
and lymphocytes did not stain for HFE, whilst the granulocytes did.
Fluorescence (FL-2 height) is shown on the horizontal axes and is in log-
arithimic scale, the numbers of cells (events) are shown on the vertical
axes. Note that the events axes are to different scales. 
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serum staining, both detected with a secondary anti-
body conjugated to the fluor FITC were performed
for each of the gated cell populations and, for com-
pleteness, all cells analyzed. In these comparisons
(Figure 2B), an increase in a given population’s fluo-
rescence is indicative of HFE CT16 antiserum stain-
ing. A subset of the ‘all cells’ population was weakly
stained by the CT16 antiserum and when the indi-
vidual cell populations were examined, this subset
was shown to be granulocytes, whilst neither lym-
phocytes nor monocytes were stained more by the
antibody than by an an equivalent concentration of
non-immune serum.
In order to both confirm and visualize the flow
cytometry results, leukocytes prepared from periph-
eral blood were attached to a microscope slide by
cytospin and subjected to immunofluorescent stain-
ing with either the CT16 antiserum or with an equiv-
alent concentration of non-immune serum. In order
to stain ‘all cells’ and to aid subcellular localization of
the staining by the CT16 antiserum, this was detect-
ed using a secondary antibody conjugated to phyco-
erythrin. Actin was detected using an anti-actin anti-
body and a FITC-conjugated secondary antibody.
Figure 3A shows the staining achieved using non-
immune rabbit serum and the secondary goat anti-
rabbit immunoglobulins conjugated with PE. This
control slide demonstrated that the red phycoerythrin
fluorescence observed in test samples was due to the
staining from the CT16 antiserum. Figure 3B-D
demonstrates the fluorescence obtained from a sam-
ple stained using the CT16 antiserum and anti-B
actin antibodies. There was a clear subset of periph-
eral blood cells with complex multi-globular nuclei
(the dark holes), consistent with granulocyte cells,
which stained for HFE (HFE CT16 antibody), whilst
the remaining cells (almost exclusively lymphocytes
in these types of preparation) were not stained for
HFE. BFU-E (harvested at 10 and 14 days) were neg-
ative on staining cytospin preparations with CT16
anti-serum (data not shown).
Discussion
It has been shown by the study of transfected cells
and knock-out mice that the HFE protein modifies
transferrin iron uptake by the transferrin receptor;
however, these observations do not provide a direct
link between loss of HFE function and enhanced iron
absorption in subjects with hereditary hemochro-
matosis and do not provide a convincing explanation
as to how the C282Y mutated protein might causes
enhanced iron absorption.17 Recently evidence has
been presented to suggest that HFE protein is
required for the regulation of hepcidin synthesis in
the liver.25 Hepcidin levels in the plasma normally
correlate with levels of storage iron and regulate iron
uptake at the apex of the intestinal mucosa by regu-
lating the synthesis of iron transport proteins includ-
ing DcytB26 and DMT1.27 The degree of regulation of
iron uptake by hepcidin in erythroid bone marrow is
not known. However, hemoglobin synthesis does
not appear to be limited in hemochromatosis as
patients can usually tolerate weekly or even twice
weekly phlebotomy of 450 mL blood.
An alternative proposal concerns the regulation of
iron supply to nucleated red cells in the bone mar-
row. If the HFE protein is expressed in erythroid pre-
cursors and HFE normally reduces iron uptake from
transferrin it is likely that the C282Y mutated protein
will permit increased erythroid iron uptake. The
resulting increase in plasma iron turnover would lead
to an increase in intestinal iron absorption and the
Erythropoiesis and HFE expression
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Figure 3. An example of the immunofluorescent staining for HFE
protein in peripheral blood leukocytes obtained using the CT16
antibody. Top left: The fluoresence obtained from a control sam-
ple subjected to staining with the non-immune serum and second-
ary antibody alone. A test sample triple stained for β-actin and
HFE is shown with its two color components, bottom left, β-actin
staining alone (green), top right, HFE CT-16 antibody staining
alone (red) and bottom right, merged demonstrating that a subset
of peripheral blood leukocytes stained positively for HFE.
deposition of iron throughout the body.21
In this study, we found that asymptomatic hemochro-
matosis subjects had normal hemoglobin and red cell
hemoglobin concentrations and red cell counts, but
slightly raised mean reticulocyte counts, indicating
increased erythropoeisis. This might be expected to lead
to an increase in serum transferrin receptor concentra-
tion but serum transferrin receptor concentrations were
low when compared to the reference range. This prob-
ably reflects the effect of the increased iron stores as the
transferrin receptor concentration correlated inversely
with transferrin saturation. Thus the current study pro-
vides evidence for an increased rate of erythropoeisis
among subjects with the hemochromatosis HFE C282Y
homozygous genotype. 
Given that loss of HFE function due to the C282Y
mutation may be associated with changes in erythroid
iron handling, we investigated the expression of HFE in
nucleated red cells and in white cells. In peripheral
blood, although granulocytes expressed HFE protein,
they no longer contained mRNA indicating that HFE
expression had been down-regulated. Monocytes
showed little expression but macrophages derived from
peripheral blood monocytes expressed HFE mRNA. No
HFE expression was detected in lymphoid cells. Among
maturing erythroid cells, cultures of primary differenti-
ated cells were found not to express HFE mRNA or pro-
tein. Currently, there is agreement that monocytes and
macrophages express HFE protein;13,16 but there are con-
flicting reports about expression of HFE in lymphoid
cells. Feder et al.2 reported weak expression of HFE on
Northern blotting and Chitamber et al.28 reported expres-
sion for lymphoblastoid cell lines derived from normal
lymphocytes. Parkilla et al.29 did not detect expression of
mRNA in lymphocytes and neither did we.
There have, to our knowledge, been no previous
reports about HFE expression in human erythroid cells,
where most iron is utilized. During erythroid develop-
ment iron uptake is maximal during the early nor-
moblast stage and declines during maturation to the
reticulocyte30. Cultured erythroid colonies (mostly
intermediate and late normoblasts) did not express
HFE protein. Therefore, it is likely that HFE does not
play a direct role in the regulation of transferrin iron
uptake by erythroid bone marrow cells. Thus transfer-
rin receptor mediated erythroid iron uptake would
proceed without the hurdle of HFE intercession.
Furthermore, within the bone marrow, erythroid cells
surround macrophages and may obtain some iron
directly from the macrophages via ferritin – a process
called rhopheocytosis by Policard and Bessis;31 this is
another process independent of the direct effects of
HFE. Erythroblasts also have ferritin receptors that can
scavenge extracellular ferritin.32 However, macro-
phages express HFE protein, and the C282Y mutation
may modify HFE function and thus iron transport
within the macrophage and so influence red cell iron
uptake.16 The quantitative significance of these path-
ways of iron supply is not well understood.
Interestingly, investigations into the effects of HFE
C282Y mutations on the levels of circulating non-
transferrin bound iron have shown that significantly
higher levels of non-transferrin bound iron, which can
catalyze lipid peroxidation, are present in both HFE
C282Y homozygotes (1.79 µmol/L) and in C282Y het-
erozygotes (0.51 µmol/L) than in control subjects (-0.3
µmol/L).33 These results indicate that greater than nor-
mal levels of non-transferrin bound iron are present in
the circulation of subjects with HFE C282Y mutations
before substantial iron loading develops. These
increased levels of non-transferrin bound iron, which
continue to increase as hereditary hemochromatosis
develops,34-37 perhaps combined with increases in intra-
cellular erythrocyte non-heme iron,38 may lead to
weakening of red cell plasma membranes,39,40, general-
ized oxidative damage,39 and shortening of the red cell
life-span. The necessary increase in the rate of erythro-
poeisis, and therefore increase in plasma iron turnover,
may be one contributor to the gradual, progressive iron
loading observed in hereditary hemochromatosis
patients.
In summary, we present new evidence of altered ery-
thropoeisis in HFE C282Y homozygotes and describe
the distribution of HFE mRNA and protein expression
in normal, peripheral blood cells and BFU-E derived
from peripheral blood cells. Despite the changes in ery-
thropoeisis, HFE expression was not found in the cells
that are most active in iron uptake and hemoglobin
production.
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